RxDoctor Payments Data

Kathryn Hook, PA

Physician Assistant · Salinas, CANPI 1528450343

Payments from drug & device makers

$3,522in general payments, 2019–2025

Across 140 payments — averaging $25.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$408
  • Sanofi$322
  • Regeneron Healthcare Solutions, Inc.$275
  • Blueprint Medicines Corporation$269
  • Novartis$236
  • plus $782 from 10 others

What the payments were for

  • Food & beverage$3,38996%
  • Education$1334%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,522 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$7,872
Medicare patients
74
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TezspireTezepelumab-Ekko11$42,161
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$35,838
Breo ElliptaFluticasone/Vilanterol34$25,645
Spiriva RespimatTiotropium Bromide22$19,027
Advair HfaFluticasone Propion/Salmeterol33$11,843
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$10,401
Wixela InhubFluticasone Propion/Salmeterol49$7,236
SymbicortBudesonide/Formoterol Fumarate20$6,652
Arnuity ElliptaFluticasone Furoate16$4,947
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$3,143
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,394
Azelastine Hcl55$2,222
Albuterol Sulfate HfaAlbuterol Sulfate58$1,981
Epinephrine13$1,930
Montelukast Sodium90$1,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$1,232$66,429109 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$408$59,21546 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →